25 XP   0   0   10

Mithra Pharmaceuticals SA
Buy, Hold or Sell?

Let's analyse Mithra together

PenkeI guess you are interested in Mithra Pharmaceuticals SA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Mithra Pharmaceuticals SA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Mithra Pharmaceuticals SA

I send you an email if I find something interesting about Mithra Pharmaceuticals SA.

Quick analysis of Mithra (30 sec.)










What can you expect buying and holding a share of Mithra? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
20.0%

What is your share worth?

Current worth
€0.50
Expected worth in 1 year
€0.49
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
€-0.01
Return On Investment
-0.8%

For what price can you sell your share?

Current Price per Share
€1.19
Expected price per share
€1.084 - €1.962
How sure are you?
50%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1. Valuation of Mithra (5 min.)




Live pricePrice per Share (EOD)

€1.19

Intrinsic Value Per Share

€-14.64 - €-10.42

Total Value Per Share

€-14.14 - €-9.92

2. Growth of Mithra (5 min.)




Is Mithra growing?

Current yearPrevious yearGrowGrow %
How rich?$37m$37.2m-$168.2k-0.5%

How much money is Mithra making?

Current yearPrevious yearGrowGrow %
Making money-$65.5m-$128.4m$62.9m96.0%
Net Profit Margin-89.0%-515.6%--

How much money comes from the company's main activities?

3. Financial Health of Mithra (5 min.)




3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

What can you expect buying and holding a share of Mithra? (5 min.)

Welcome investor! Mithra's management wants to use your money to grow the business. In return you get a share of Mithra.

What can you expect buying and holding a share of Mithra?

First you should know what it really means to hold a share of Mithra. And how you can make/lose money.

Speculation

The Price per Share of Mithra is €1.188. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Mithra.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Mithra, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €0.50. Based on the TTM, the Book Value Change Per Share is €0.00 per quarter. Based on the YOY, the Book Value Change Per Share is €-1.85 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Mithra.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.98-82.5%-0.98-82.5%-1.92-161.7%-1.01-85.1%-0.64-54.2%
Usd Book Value Change Per Share0.00-0.2%0.00-0.2%-2.04-171.4%-0.17-14.7%0.054.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.4%
Usd Total Gains Per Share0.00-0.2%0.00-0.2%-2.04-171.4%-0.17-14.7%0.064.8%
Usd Price Per Share3.74-3.74-21.97-19.65-13.07-
Price to Earnings Ratio-3.82--3.82--11.44--40.79--31.03-
Price-to-Total Gains Ratio-1,489.04--1,489.04--10.79--314.86--212.28-
Price to Book Ratio6.76-6.76-39.50-14.85-9.40-
Price-to-Total Gains Ratio-1,489.04--1,489.04--10.79--314.86--212.28-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.3060872
Number of shares765
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.00-0.17
Usd Total Gains Per Share0.00-0.17
Gains per Quarter (765 shares)-1.92-133.73
Gains per Year (765 shares)-7.69-534.93
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-8-180-535-545
20-15-260-1070-1080
30-23-340-1605-1615
40-31-420-2140-2150
50-38-500-2675-2685
60-46-580-3210-3220
70-54-660-3745-3755
80-62-740-4279-4290
90-69-820-4814-4825
100-77-900-5349-5360

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.011.00.00.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%5.05.00.050.0%6.05.00.054.5%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%2.00.08.020.0%2.00.09.018.2%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%5.05.00.050.0%6.05.00.054.5%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Fundamentals of Mithra

About Mithra Pharmaceuticals SA

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

Fundamental data was last updated by Penke on 2023-11-09 02:26:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.1. Profitability of Mithra Pharmaceuticals SA.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Mithra earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Mithra to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -89.0% means that €-0.89 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Mithra Pharmaceuticals SA:

  • The MRQ is -89.0%. The company is making a huge loss. -2
  • The TTM is -89.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-89.0%TTM-89.0%0.0%
TTM-89.0%YOY-515.6%+426.6%
TTM-89.0%5Y-340.1%+251.1%
5Y-340.1%10Y-204.9%-135.2%
1.1.2. Return on Assets

Shows how efficient Mithra is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Mithra to the Drug Manufacturers - Specialty & Generic industry mean.
  • -13.5% Return on Assets means that Mithra generated €-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Mithra Pharmaceuticals SA:

  • The MRQ is -13.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -13.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.5%TTM-13.5%0.0%
TTM-13.5%YOY-27.7%+14.2%
TTM-13.5%5Y-14.7%+1.2%
5Y-14.7%10Y-14.4%-0.3%
1.1.3. Return on Equity

Shows how efficient Mithra is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Mithra to the Drug Manufacturers - Specialty & Generic industry mean.
  • -177.0% Return on Equity means Mithra generated €-1.77 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Mithra Pharmaceuticals SA:

  • The MRQ is -177.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -177.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-177.0%TTM-177.0%0.0%
TTM-177.0%YOY-345.4%+168.4%
TTM-177.0%5Y-123.1%-53.8%
5Y-123.1%10Y-96.9%-26.3%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.2. Operating Efficiency of Mithra Pharmaceuticals SA.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Mithra is operating .

  • Measures how much profit Mithra makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Mithra to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 4.5% means the company generated €0.05  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Mithra Pharmaceuticals SA:

  • The MRQ is 4.5%. The company is operating less efficient.
  • The TTM is 4.5%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ4.5%TTM4.5%0.0%
TTM4.5%YOY-387.7%+392.2%
TTM4.5%5Y-251.7%+256.2%
5Y-251.7%10Y-166.3%-85.4%
1.2.2. Operating Ratio

Measures how efficient Mithra is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.39 means that the operating costs are €1.39 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 1.392. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.392. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.392TTM1.3920.000
TTM1.392YOY4.877-3.485
TTM1.3925Y3.604-2.212
5Y3.60410Y2.630+0.974
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.3. Liquidity of Mithra Pharmaceuticals SA.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Mithra is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.12 means the company has €1.12 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 1.118. The company is just able to pay all its short-term debts.
  • The TTM is 1.118. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.118TTM1.1180.000
TTM1.118YOY1.038+0.081
TTM1.1185Y2.340-1.222
5Y2.34010Y1.966+0.374
1.3.2. Quick Ratio

Measures if Mithra is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Mithra to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.73 means the company can pay off €0.73 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 0.726. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.726. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.726TTM0.7260.000
TTM0.726YOY0.474+0.252
TTM0.7265Y1.830-1.104
5Y1.83010Y2.036-0.206
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.4. Solvency of Mithra Pharmaceuticals SA.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Mithra assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Mithra to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.92 means that Mithra assets are financed with 92.4% credit (debt) and the remaining percentage (100% - 92.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 0.924. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.924. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.924TTM0.9240.000
TTM0.924YOY0.920+0.004
TTM0.9245Y0.741+0.183
5Y0.74110Y0.689+0.052
1.4.2. Debt to Equity Ratio

Measures if Mithra is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Mithra to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 1,213.3% means that company has €12.13 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 12.133. The company is unable to pay all its debts with equity. -1
  • The TTM is 12.133. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ12.133TTM12.1330.000
TTM12.133YOY11.468+0.665
TTM12.1335Y5.741+6.393
5Y5.74110Y4.582+1.158
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

2. Market Valuation of Mithra Pharmaceuticals SA

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Mithra generates.

  • Above 15 is considered overpriced but always compare Mithra to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -3.82 means the investor is paying €-3.82 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Mithra Pharmaceuticals SA:

  • The EOD is -1.333. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.821. Based on the earnings, the company is expensive. -2
  • The TTM is -3.821. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.333MRQ-3.821+2.488
MRQ-3.821TTM-3.8210.000
TTM-3.821YOY-11.438+7.617
TTM-3.8215Y-40.791+36.970
5Y-40.79110Y-31.026-9.765
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Mithra Pharmaceuticals SA:

  • The EOD is -0.964. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.762. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.762. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.964MRQ-2.762+1.799
MRQ-2.762TTM-2.7620.000
TTM-2.762YOY-13.988+11.226
TTM-2.7625Y-52.548+49.785
5Y-52.54810Y-31.524-21.023
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Mithra is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 6.76 means the investor is paying €6.76 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Mithra Pharmaceuticals SA:

  • The EOD is 2.360. Based on the equity, the company is underpriced. +1
  • The MRQ is 6.763. Based on the equity, the company is overpriced. -1
  • The TTM is 6.763. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD2.360MRQ6.763-4.403
MRQ6.763TTM6.7630.000
TTM6.763YOY39.504-32.741
TTM6.7635Y14.850-8.087
5Y14.85010Y9.401+5.449
2. Total Gains per Share

2.4. Latest News of Mithra Pharmaceuticals SA

Does Mithra Pharmaceuticals SA still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Mithra Pharmaceuticals SA to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2023-11-07
07:00
Mithra’s NEXTSTELLIS® granted additional patent in the United StatesRead
2023-11-06
18:52
Mithra releases invitation to its extraordinary securities holders’ meetingRead
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Mithra Pharmaceuticals SA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.002-0.0020%-1.852+80878%-0.159+6854%0.047-105%
Book Value Per Share--0.5030.5030%0.5060%1.613-69%1.278-61%
Current Ratio--1.1181.1180%1.038+8%2.340-52%1.966-43%
Debt To Asset Ratio--0.9240.9240%0.920+0%0.741+25%0.689+34%
Debt To Equity Ratio--12.13312.1330%11.468+6%5.741+111%4.582+165%
Dividend Per Share----0%-0%-0%0.004-100%
Eps---0.891-0.8910%-1.747+96%-0.919+3%-0.586-34%
Free Cash Flow Per Share---1.233-1.2330%-1.428+16%-1.026-17%-0.693-44%
Free Cash Flow To Equity Per Share---0.069-0.0690%-1.081+1470%0.044-255%0.131-153%
Gross Profit Margin--1.0351.0350%1.016+2%1.0390%1.363-24%
Intrinsic Value_10Y_max---10.423--------
Intrinsic Value_10Y_min---14.643--------
Intrinsic Value_1Y_max---0.771--------
Intrinsic Value_1Y_min---1.406--------
Intrinsic Value_3Y_max---2.524--------
Intrinsic Value_3Y_min---4.303--------
Intrinsic Value_5Y_max---4.529--------
Intrinsic Value_5Y_min---7.263--------
Market Cap79487179.200-187%227823102.000227823102.0000%1336829832.000-83%1195586199.600-81%795139425.600-71%
Net Profit Margin---0.890-0.8900%-5.156+479%-3.401+282%-2.049+130%
Operating Margin--0.0450.0450%-3.877+8652%-2.517+5652%-1.663+3769%
Operating Ratio--1.3921.3920%4.877-71%3.604-61%2.630-47%
Pb Ratio2.360-187%6.7636.7630%39.504-83%14.850-54%9.401-28%
Pe Ratio-1.333+65%-3.821-3.8210%-11.438+199%-40.791+967%-31.026+712%
Price Per Share1.188-187%3.4053.4050%19.980-83%17.869-81%11.884-71%
Price To Free Cash Flow Ratio-0.964+65%-2.762-2.7620%-13.988+406%-52.548+1802%-31.524+1041%
Price To Total Gains Ratio-519.524+65%-1489.040-1489.0400%-10.790-99%-314.862-79%-212.280-86%
Quick Ratio--0.7260.7260%0.474+53%1.830-60%2.036-64%
Return On Assets---0.135-0.1350%-0.277+106%-0.147+9%-0.144+7%
Return On Equity---1.770-1.7700%-3.454+95%-1.231-30%-0.969-45%
Total Gains Per Share---0.002-0.0020%-1.852+80878%-0.159+6854%0.051-104%
Usd Book Value--37035487.80037035487.8000%37203696.0000%118615365.400-69%93972094.520-61%
Usd Book Value Change Per Share---0.003-0.0030%-2.036+80878%-0.175+6854%0.052-105%
Usd Book Value Per Share--0.5540.5540%0.5560%1.773-69%1.404-61%
Usd Dividend Per Share----0%-0%-0%0.005-100%
Usd Eps---0.980-0.9800%-1.920+96%-1.011+3%-0.644-34%
Usd Free Cash Flow---90675213.800-90675213.8000%-105068558.600+16%-75449403.320-17%-50979068.060-44%
Usd Free Cash Flow Per Share---1.355-1.3550%-1.570+16%-1.128-17%-0.762-44%
Usd Free Cash Flow To Equity Per Share---0.076-0.0760%-1.188+1470%0.049-255%0.144-153%
Usd Market Cap87388204.812-187%250468718.339250468718.3390%1469710717.301-83%1314427467.840-81%874176284.505-71%
Usd Price Per Share1.306-187%3.7433.7430%21.966-83%19.645-81%13.065-71%
Usd Profit---65545128.600-65545128.6000%-128491275.600+96%-71111170.920+8%-45760436.140-30%
Usd Revenue--73656501.80073656501.8000%24921199.200+196%55649649.080+32%41662972.340+77%
Usd Total Gains Per Share---0.003-0.0030%-2.036+80878%-0.175+6854%0.057-104%
 EOD+3 -5MRQTTM+0 -0YOY+23 -115Y+14 -2010Y+7 -29

3.2. Fundamental Score

Let's check the fundamental score of Mithra Pharmaceuticals SA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.333
Price to Book Ratio (EOD)Between0-12.360
Net Profit Margin (MRQ)Greater than0-0.890
Operating Margin (MRQ)Greater than00.045
Quick Ratio (MRQ)Greater than10.726
Current Ratio (MRQ)Greater than11.118
Debt to Asset Ratio (MRQ)Less than10.924
Debt to Equity Ratio (MRQ)Less than112.133
Return on Equity (MRQ)Greater than0.15-1.770
Return on Assets (MRQ)Greater than0.05-0.135
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Mithra Pharmaceuticals SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.184
Ma 20Greater thanMa 501.271
Ma 50Greater thanMa 1001.333
Ma 100Greater thanMa 2001.754
OpenGreater thanClose1.154
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Other Assets  47,93556,007103,942-103,941101-2-1
EBITDA  -31,1805,164-26,016-66,711-92,727-2,867-95,594110,57114,977
Depreciation and Amortization  -45,368-6,696-52,06443,015-9,0491,331-7,71819,65811,940
Tax Provision  -9,8854,757-5,128-13,707-18,83511,940-6,89555,03448,139
Income Tax Expense  -9,8854,757-5,128-13,707-18,83511,940-6,89555,03448,139



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets442,414
Total Liabilities408,727
Total Stockholder Equity33,687
 As reported
Total Liabilities 408,727
Total Stockholder Equity+ 33,687
Total Assets = 442,414

Assets

Total Assets442,414
Total Current Assets145,863
Long-term Assets145,863
Total Current Assets
Cash And Cash Equivalents 28,285
Net Receivables 66,398
Inventory 50,312
Other Current Assets 868
Total Current Assets  (as reported)145,863
Total Current Assets  (calculated)145,863
+/-0
Long-term Assets
Property Plant Equipment 106,252
Goodwill 5,233
Intangible Assets 134,905
Long-term Assets Other 33,808
Long-term Assets  (as reported)296,552
Long-term Assets  (calculated)280,198
+/- 16,354

Liabilities & Shareholders' Equity

Total Current Liabilities130,431
Long-term Liabilities278,296
Total Stockholder Equity33,687
Total Current Liabilities
Short-term Debt 52,411
Short Long Term Debt 47,232
Accounts payable 31,716
Other Current Liabilities 46,304
Total Current Liabilities  (as reported)130,431
Total Current Liabilities  (calculated)177,663
+/- 47,232
Long-term Liabilities
Long term Debt 137,762
Capital Lease Obligations 43,432
Long-term Liabilities Other 8,124
Long-term Liabilities  (as reported)278,296
Long-term Liabilities  (calculated)189,318
+/- 88,978
Total Stockholder Equity
Common Stock41,228
Retained Earnings -396,254
Other Stockholders Equity 388,713
Total Stockholder Equity (as reported)33,687
Total Stockholder Equity (calculated)33,687
+/-0
Other
Capital Stock41,228
Cash and Short Term Investments 28,285
Common Stock Shares Outstanding 49,059
Liabilities and Stockholders Equity 442,414
Net Debt 200,141
Net Invested Capital 218,681
Net Working Capital 15,432
Short Long Term Debt Total 228,426



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-31
> Total Assets 
1,551
2,716
3,050
3,676
5,814
7,451
7,249
13,984
13,543
9,648
11,904
61,019
205,587
172,696
244,712
355,684
397,643
521,985
421,918
442,414
442,414421,918521,985397,643355,684244,712172,696205,58761,01911,9049,64813,54313,9847,2497,4515,8143,6763,0502,7161,551
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
6,272
8,103
8,682
109,089
57,876
74,212
153,667
91,522
238,475
99,389
145,863
145,86399,389238,47591,522153,66774,21257,876109,0898,6828,1036,272000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
703
1,561
2,113
7,794
2,150
36,190
118,949
49,720
138,675
32,872
28,285
28,28532,872138,67549,720118,94936,1902,1507,7942,1131,561703000000000
       Short-term Investments 
598
784
262
974
505
636
1,013
460
158
0
0
0
89,000
43,600
0
0
46
14
-9,312
0
0-9,31214460043,60089,0000001584601,013636505974262784598
       Net Receivables 
137
977
1,767
1,289
2,753
3,617
2,483
8,345
5,734
3,146
4,112
3,367
5,951
6,840
31,699
7,914
25,480
63,597
21,820
66,398
66,39821,82063,59725,4807,91431,6996,8405,9513,3674,1123,1465,7348,3452,4833,6172,7531,2891,767977137
       Other Current Assets 
0
0
0
0
0
0
0
87
135
3,157
4,129
4,806
9,498
7,956
33,881
1,508
-1
807
845
868
868845807-11,50833,8817,9569,4984,8064,1293,157135870000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
3,376
3,801
52,337
96,498
114,820
170,500
202,017
306,121
283,509
322,528
296,552
296,552322,528283,509306,121202,017170,500114,82096,49852,3373,8013,376000000000
       Property Plant Equipment 
35
95
164
237
1,051
1,213
1,131
1,054
1,134
1,069
1,456
2,440
3,574
16,961
59,520
84,396
94,037
99,496
107,677
106,252
106,252107,67799,49694,03784,39659,52016,9613,5742,4401,4561,0691,1341,0541,1311,2131,0512371649535
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
3,814
8,016
5,233
5,233
5,233
5,233
5,233
5,233
5,233
5,2335,2335,2335,2335,2335,2335,2338,0163,81400000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
214
2,119
198
165
0
0
22,860
0
0
0
00022,860001651982,1192140000000000
       Intangible Assets 
650
538
354
735
568
486
416
1,826
1,960
1,887
1,725
41,649
78,234
79,130
80,385
81,907
87,490
89,005
104,954
134,905
134,905104,95489,00587,49081,90780,38579,13078,23441,6491,7251,8871,9601,826416486568735354538650
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
61
463
3,871
90,131
44,738
2,644
3,436
62,116
20,796
-2
33,808
33,808-220,79662,1163,4362,64444,73890,1313,87146361000000000
> Total Liabilities 
591
1,665
1,911
2,087
3,836
4,894
6,167
10,391
9,577
7,643
9,416
55,495
78,193
79,681
157,830
204,791
234,345
364,248
388,078
408,727
408,727388,078364,248234,345204,791157,83079,68178,19355,4959,4167,6439,57710,3916,1674,8943,8362,0871,9111,665591
   > Total Current Liabilities 
293
1,439
1,721
1,516
2,802
3,908
4,541
7,853
7,615
6,315
8,177
28,916
34,540
27,705
52,217
36,081
47,799
70,747
95,793
130,431
130,43195,79370,74747,79936,08152,21727,70534,54028,9168,1776,3157,6157,8534,5413,9082,8021,5161,7211,439293
       Short-term Debt 
0
0
0
0
0
0
0
0
0
3,597
3,446
23,214
17,854
6,955
16,237
12,578
13,272
18,792
53,128
52,411
52,41153,12818,79213,27212,57816,2376,95517,85423,2143,4463,597000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
4,685
105
904
6,955
16,237
10,443
6,526
11,477
46,567
47,232
47,23246,56711,4776,52610,44316,2376,9559041054,6850000000000
       Accounts payable 
42
1,282
1,270
1,185
1,771
2,816
2,710
3,695
2,136
1,418
2,581
5,393
4,613
9,312
16,141
13,071
19,449
23,325
16,915
31,716
31,71616,91523,32519,44913,07116,1419,3124,6135,3932,5811,4182,1363,6952,7102,8161,7711,1851,2701,28242
       Other Current Liabilities 
110
58
293
138
413
383
530
2,765
2,667
1,300
2,150
309
12,073
11,438
19,839
10,432
789
1,259
1,620
46,304
46,3041,6201,25978910,43219,83911,43812,0733092,1501,3002,6672,76553038341313829358110
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
1,328
1,239
26,579
43,653
51,976
105,613
168,710
186,546
293,501
292,285
278,296
278,296292,285293,501186,546168,710105,61351,97643,65326,5791,2391,328000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
29,183
39,987
48,736
67,370
64,784
0
0
0
00064,78467,37048,73639,98729,183000000000000
       Other Liabilities 
0
0
0
136
0
0
0
19
38
1
0
0
5,957
3,734
2,365
6,484
8,809
8,336
9,251
0
09,2518,3368,8096,4842,3653,7345,9570013819000136000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,575
3,105
7,441
12,036
19,917
0
019,91712,0367,4413,1051,57500000000000000
> Total Stockholder Equity
961
1,051
1,140
1,589
1,978
2,557
1,082
3,593
3,966
2,005
2,488
5,524
127,394
93,015
86,882
150,893
163,298
157,737
33,840
33,687
33,68733,840157,737163,298150,89386,88293,015127,3945,5242,4882,0053,9663,5931,0822,5571,9781,5891,1401,051961
   Common Stock
1,919
3,136
3,153
3,376
3,380
3,380
3,480
2,480
2,480
2,480
5,041
3,107
22,613
22,613
25,036
26,925
28,018
31,271
32,250
41,228
41,22832,25031,27128,01826,92525,03622,61322,6133,1075,0412,4802,4802,4803,4803,3803,3803,3763,1533,1361,919
   Retained Earnings Total Equity00000000000000000000
   Accumulated Other Comprehensive Income 00-7,451-4,925-5,617-3,265-1,604-1,232-1,036-700-545000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
122,830
122,830
148,279
221,587
259,529
0
0
0
000259,529221,587148,279122,830122,830000000000000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
545
700
11,607
124,037
124,390
151,485
227,142
262,953
346,225
338,223
388,713
388,713338,223346,225262,953227,142151,485124,390124,03711,607700545000000000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.